Comparative Effects of Lidocaine, Esmolol, and Nitroglycerin in Modifying the Hemodynamic Response to Laryngoscopy and Intubation

Singh, Harbhej; Vichitvejpaisal, Phongthara; Gaines, George Y.; White, Paul F.

doi:10.1097/00132586-199602000-00054

Cited by 31 publications

(55 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Various methods such as α or β adrenergic blockers, opioids, topical or systemic lignocaine are being used to attenuate hemodynamic response [13][14][15]. Dexmedetomidine possess anxiolytic, sedative, analgesic, and sympatholytic properties.…”

Section: Discussionmentioning

confidence: 99%

Dexmedetomidine Versus Oral Pregabalin to Attenuate Hemodynamic Response to Laryngoscopy and Orotracheal Intubation: A Comparative Study

Samal

Pattnaik

Swain

et al. 2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objectives: The airway instrumentation of direct laryngoscopy and tracheal intubation is powerful noxious stimuli that should be attenuated by appropriate premedication, smooth induction, and rapid intubation. This study compared the efficacy intravenous dexmedetomidine and oral pregabalin premedication for attenuation of hemodynamic pressor response to laryngoscopy and intubation.Methods: A total of 60 patients of age group 20-50 years scheduled for elective surgeries under general anesthesia with American Society of Anesthesiologists physical Status I and II were divided into two groups each of 30. Group D received intravenous dexmedetomidine 1 mcg/kg over 10 minutes before induction, and Group P received oral pregabalin 150 mg 1 hr before intubation. Parameters observed were heart rate (HR) and mean arterial pressure (MAP) at baseline, after induction, immediately after intubation and then 5, 10, 15, and 30 minutes thereafter.Results: Attenuation of HR in group dexmedetomidine (78.12±10.0/minutes) immediately after intubation was statistically significant than group pregabalin (89.76±10.45/minutes). MAP significantly (p<0.05) decreased after intubation with dexmedetomidine. As compared to oral pregabalin, attenuation of HR and MAP was statistically significant till 30 minutes after intubation with intravenous dexmedetomidine. Conclusion:Intravenous dexmedetomidine 1 µg/kg is more effective than oral pregabalin 150 mg in attenuating hemodynamic response to laryngoscopy and orotracheal intubation.

show abstract

Section: Discussionmentioning

confidence: 99%

Dexmedetomidine Versus Oral Pregabalin to Attenuate Hemodynamic Response to Laryngoscopy and Orotracheal Intubation: A Comparative Study

Samal

Pattnaik

Swain

et al. 2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

show abstract

“…The first article obtained was a randomized, placebo-controlled, double-blinded study in which the efficacy of intravenous (IV) lidocaine, esmolol, and nitroglycerin were each individually considered for the purpose of attenuating the hemodynamic response of anesthetized patients to laryngoscopy and intubation (Singh et al 1995). According to the Joanna Briggs Institute, this study method is indicative of a level of evidence of 1.c (Appendix I) (The Joanna Briggs Institute 2013).…”

Section: Resultsmentioning

confidence: 99%

“…They and others established that the induction of anesthesia with associated respiratory tract irritation due to laryngoscopy and intubation often results in a hemodynamic response comprised of symptoms such as hypertension and tachycardia (Reid & Brace 1940, Kovac 1996, Aghdaii et al 2015, Sarkilar et al 2015. Since the description of this phenomenon in 1940, there have been various anesthetic drug combinations and hemodynamic-moderating efforts that researchers have trialed over the years in an effort to attenuate this sudden, and often dramatic, hemodynamic response -several of which are targeted in this review (Singh et al 1995, van den Berg et al 1997, Gupta et al 2009). However, no specific regimen or drug combination has demonstrated consistent and convincing outcomes in the mediation of this response across the majority of patients requiring endotracheal intubation.…”

Section: Introductionmentioning

confidence: 99%

Esmolol vs. nitroglycerin: attenuating hemodynamic response to laryngoscopy and intubation

Held

2016

IJANS

View full text Add to dashboard Cite

Hemodynamic response to laryngoscopy and intubation is a common occurrence with the potential for harmful effects. Many drugs have been utilized throughout the years to attenuate this response with mixed results. This review compares the efficacy of two drugs, esmolol and nitroglycerin, in attenuating hemodynamic response to laryngoscopy and intubation. A systematic review was performed compiling all previous studies detailing the efficacy of esmolol in comparison to nitroglycerin for this purpose. Esmolol was found to consistently attenuate hemodynamic responses of blood pressure and heart rate with greater efficacy than nitroglycerin, and is thus recommended over nitroglycerin for use in this role.

show abstract

“…Singh ve ark. (12) , 1,4 mg/kg olarak kullanılan esmolol dozunun entübasyona hemodinamik yanıtı önle-mede etkili olduğunu göstermiştir. Bensky ve ark.…”

Section: Discussionunclassified

Effect of Esmolol on Hemodynamic Response to Tracheal Intubation in Hyper- and Normotensive Patients

Ökten¹,

Ceyhan²,

Sabuncu³

2011

J Turk Anaesth Int Care

View full text Add to dashboard Cite

Comparative Effects of Lidocaine, Esmolol, and Nitroglycerin in Modifying the Hemodynamic Response to Laryngoscopy and Intubation

Cited by 31 publications

References 0 publications

Dexmedetomidine Versus Oral Pregabalin to Attenuate Hemodynamic Response to Laryngoscopy and Orotracheal Intubation: A Comparative Study

Dexmedetomidine Versus Oral Pregabalin to Attenuate Hemodynamic Response to Laryngoscopy and Orotracheal Intubation: A Comparative Study

Esmolol vs. nitroglycerin: attenuating hemodynamic response to laryngoscopy and intubation

Effect of Esmolol on Hemodynamic Response to Tracheal Intubation in Hyper- and Normotensive Patients

Contact Info

Product

Resources

About